Literature DB >> 1381404

A comparison of specific IgG antibody levels to the cell wall mannan of Candida albicans in normal individuals and in patients with primary antibody deficiency.

J A Faux1, A E Agbarakwe, S A Misbah, H M Chapel.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) has been developed to measure specific IgG antibody to the polysaccharide, cell wall mannan of Candida albicans (mannan). The results were expressed as arbitrary units/ml, with an inter- and intra-assay coefficient of variation of 7-11%. In establishing normal ranges we found that specific IgG to the mannan increased with age, with 18% of healthy children aged 3-10, 48% of healthy children aged 11-19 and 76% of an adult donor population having specific IgG antibody to mannan (greater than 30 U/ml). We have compared these normal ranges, with a group of patients with primary antibody deficiency (PAD). None of the 23 patients with PAD, which included common variable immunodeficiency, IgG subclass deficiency, and selective IgA deficiency, had titres greater than 30 U/ml. The patients with PAD had significantly lower levels of specific IgG anti-mannan antibody (median 9 U/ml) compared to healthy children aged 11-19 (median 26 U/ml) or adults (median 58 U/ml) (p = less than 0.001) but not children aged 3-10, (median 1 U/ml) (p = 0.08).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381404     DOI: 10.1016/0022-1759(92)90319-o

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.

Authors:  Francis Jacob; Darlene R Goldstein; Nicolai V Bovin; Tatiana Pochechueva; Marianne Spengler; Rosemarie Caduff; Daniel Fink; Marko I Vuskovic; Margaret E Huflejt; Viola Heinzelmann-Schwarz
Journal:  Int J Cancer       Date:  2011-04-25       Impact factor: 7.396

2.  Enzyme immunoassays for specific IgG and IgE antibodies to Pichia pastoris components in normal humans.

Authors:  W Ohtani; K Kobayashi; T Ohmura
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

3.  Diagnostic value of anti-Candida enolase antibodies.

Authors:  A J van Deventer; H J van Vliet; W C Hop; W H Goessens
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

4.  The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein.

Authors:  T Meri; A M Blom; A Hartmann; D Lenk; S Meri; P F Zipfel
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  Biological activities of naturally occurring antibodies reactive with Candida albicans mannan.

Authors:  Thomas R Kozel; Randall S MacGill; Ann Percival; Qing Zhou
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 6.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 7.  The emerging world of the fungal microbiome.

Authors:  Gary B Huffnagle; Mairi C Noverr
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

Review 8.  Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.

Authors:  Aisling F Brown; John M Leech; Thomas R Rogers; Rachel M McLoughlin
Journal:  Front Immunol       Date:  2014-01-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.